A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer
暂无分享,去创建一个
C. Shapiro | B. Arun | D. Tripathy | D. Grady | G. Kimmick | E. Shtivelman | M. Tagliaferri | I. Cohen | M. Schactman | Alejandra T. Perez | H. Shaw | K. Caygill
[1] P. Conte,et al. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. , 2009, The oncologist.
[2] F. Xie,et al. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells , 2009, Molecular Cancer.
[3] J. Lee,et al. Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.
[4] Alvin T. Lo,et al. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells , 2008, Cancer biology & therapy.
[5] S. Franco,et al. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer , 2007, Breast Cancer Research and Treatment.
[6] D. Newman,et al. Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.
[7] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[8] M. Campbell,et al. In vitro anticancer activity of twelve Chinese medicinal herbs , 2005, Phytotherapy research : PTR.
[9] Mark S Butler,et al. The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.
[10] David J Newman,et al. Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.
[11] F. Hamdy,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[12] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[13] D. Tripathy,et al. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. , 2002, Anticancer research.